Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 3,100 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $37.50, for a total value of $116,250.00. Following the sale, the chairman now owns 1,621,655 shares of the company’s stock, valued at approximately $60,812,062.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total value of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $36.50, for a total value of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $35.50, for a total value of $887,500.00.

Shares of Emergent Biosolutions, Inc. (NYSE:EBS) traded up 0.22% during midday trading on Wednesday, reaching $36.47. The company’s stock had a trading volume of 217,239 shares. Emergent Biosolutions, Inc. has a 52 week low of $24.47 and a 52 week high of $37.50. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 23.23 and a beta of 1.23. The company has a 50 day moving average of $35.70 and a 200-day moving average of $32.20.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million during the quarter, compared to analysts’ expectations of $111.57 million. During the same period in the previous year, the company posted ($0.05) earnings per share. Emergent Biosolutions’s quarterly revenue was up 10.4% on a year-over-year basis. Equities research analysts predict that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/06/fuad-el-hibri-sells-3100-shares-of-emergent-biosolutions-inc-ebs-stock.html.

Several large investors have recently made changes to their positions in EBS. Bank of Montreal Can raised its holdings in shares of Emergent Biosolutions by 0.4% in the first quarter. Bank of Montreal Can now owns 113,198 shares of the biopharmaceutical company’s stock valued at $3,288,000 after buying an additional 473 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Emergent Biosolutions by 2.2% during the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the biopharmaceutical company’s stock worth $409,000 after acquiring an additional 300 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Emergent Biosolutions by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 100 shares during the period. Strs Ohio increased its stake in shares of Emergent Biosolutions by 4.1% during the first quarter. Strs Ohio now owns 178,800 shares of the biopharmaceutical company’s stock worth $5,192,000 after acquiring an additional 7,000 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Emergent Biosolutions by 3.2% during the first quarter. Russell Investments Group Ltd. now owns 460,248 shares of the biopharmaceutical company’s stock worth $13,366,000 after acquiring an additional 14,295 shares during the period. 85.44% of the stock is owned by institutional investors and hedge funds.

EBS has been the subject of several analyst reports. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $44.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.